Accepted for Publication: February 21, 2013.
Author Contributions:Study concept and design: All authors.
Acquisition of data: Weisleder.
Analysis and interpretation of data: Weisleder.
Drafting of the manuscript: All authors.
Obtained funding: Weisleder.
Administrative, technical, and material support: Alloush.
Study supervision: Weisleder.
Published Online: May 13, 2013. doi:10.1001/jamaneurol.2013.469
Conflict of Interest Disclosures: Dr Weisleder reports serving as cofounder and chief scientific officer of TRIM-edicine, Inc, a biotechnology company developing rhMG53 as a therapeutic protein.
Funding/Support: This study was supported by grant AR063084 from the National Institutes of Health and the Muscular Dystrophy Association (Dr Weisleder).
Additional Contributions: Eric X. Beck provided helpful comments on the manuscript.